Literature DB >> 19443353

Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.

Patricia De Cremoux1, Laure Grandin, Véronique Diéras, Alexia Savignoni, Armelle Degeorges, Rémy Salmon, Marc A Bollet, Fabien Reyal, Brigitte Sigal-Zafrani, Anne Vincent-Salomon, Xavier Sastre-Garau, Henri Magdelénat, Laurent Mignot, Alain Fourquet.   

Abstract

UNLABELLED: This retrospective analysis was designed to confirm the predictive role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) in the outcome of early stage, node-negative breast cancer patients. PATIENTS AND METHODS: Node-negative patients having not received adjuvant chemotherapy, and for whom frozen samples were available, were selected.
RESULTS: Among the 169 patients included, 56.8% presented with uPA >3 ng/mg of proteins and/or PAI-1 >14 ng/mg of proteins. The median follow-up was 73 months. Significant correlations were found between uPA and disease-free survival (p [univariate]=0.003; p [multivariate]=0.01), and between uPA, PAI-1, and uPA plus PAI-1 and distant relapses (p=0.002). No significant correlation was found between uPA/PAI-1 and the risk of locoregional recurrence.
CONCLUSION: This study demonstrated that uPA and PAI-1 are useful predictors of distant metastases in a subset of early stage, node-negative breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443353

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis.

Authors:  Troy A McEachron; Rafal Pawlinski; Kristy L Richards; Frank C Church; Nigel Mackman
Journal:  Blood       Date:  2010-08-24       Impact factor: 22.113

2.  Electrochemical Activity Assay for Protease Analysis Using Carbon Nanofiber Nanoelectrode Arrays.

Authors:  Yang Song; Huafang Fan; Morgan J Anderson; Jestin Gage Wright; Duy H Hua; Jessica Koehne; M Meyyappan; Jun Li
Journal:  Anal Chem       Date:  2019-02-15       Impact factor: 6.986

Review 3.  Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.

Authors:  Muhammad Tufail; Jia Cui; Changxin Wu
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

4.  Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.

Authors:  Chia-Yen Huang; Ming-Cheng Chang; Wei-Yun Huang; Ching-Ting Huang; Yu-Chien Tang; Hsien-Da Huang; Kuan-Ting Kuo; Chi-An Chen; Wen-Fang Cheng
Journal:  Sci Rep       Date:  2015-06-02       Impact factor: 4.379

5.  Inhibition of urokinase-type plasminogen activator expression by dihydroartemisinin in breast cancer cells.

Authors:  Shuqun Zhang; Yinan Ma; Jiantao Jiang; Zhijun Dai; Xiaoyan Gao; Xiaoran Yin; Wentao Xi; Weili Min
Journal:  Oncol Lett       Date:  2014-02-27       Impact factor: 2.967

6.  Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients.

Authors:  Nina Fokter Dovnik; Iztok Takac
Journal:  Radiol Oncol       Date:  2016-05-09       Impact factor: 2.991

7.  Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.

Authors:  Maja Lampelj; Darja Arko; Nina Cas-Sikosek; Rajko Kavalar; Maja Ravnik; Barbara Jezersek-Novakovic; Sarah Dobnik; Nina Fokter Dovnik; Iztok Takac
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991

8.  Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis.

Authors:  Yolanda M Fortenberry; Stephanie M Brandal; Gilles Carpentier; Malvi Hemani; Arvind P Pathak
Journal:  PLoS One       Date:  2016-10-18       Impact factor: 3.240

Review 9.  The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas.

Authors:  Monica Fedele; Laura Cerchia; Gennaro Chiappetta
Journal:  Cancers (Basel)       Date:  2017-09-30       Impact factor: 6.639

10.  SERPINA11 Inhibits Metastasis in Hepatocellular Carcinoma by Suppressing MEK/ERK Signaling Pathway.

Authors:  Ye Song; Zhuo Li; Lei Li; Houming Zhou; Ting-Ting Zeng; Chuan Jin; Jin-Rong Lin; Sha Gao; Yan Li; Xin-Yuan Guan; Ying-Hui Zhu
Journal:  J Hepatocell Carcinoma       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.